Please note: AABB reserves the right to make updates to this program.
Live Program Date: Thursday, May 17, 2018 -
Master Program Number: 18EL-334 (see program format numbers below under Registration)
Educational Track: Technical/Clinical
Topic: Cellular Therapies
Intended Audience: Medical Directors, Nurses, Physicians, Research Scientist, Resident/Fellow, Scientists, Students (MD, MT, SBB)
Teaching Level: Intermediate to Advanced
Director/Moderator: Thomas Spitzer, MD, Director, Cellular Therapy and Transplantation Laboratory, Massachusetts General Hospital, Boston, MA
Speakers: Bimalangshu R. Dey, MD, Staff Physician, Bone Marrow Transplant Program, Massachusetts General Hospital, Boston, MA; John Reagan, MD, Rhode Island Hospital, Providence, RI
After participating in this educational activity, participants should be able to:
- Apply principles of T-cell cell immunobiology to anti-tumor responses generated by hematopoietic graft rejection.
- Discuss the emerging role of microtransplantation for the treatment of acute leukemia.
- Recognize the potential to achieve anti-tumor responses after cellular therapy without the risk of graft-vs-host disease.
This program will include speakers who will address the emerging concept of hematopoietic graft rejection as a mechanism of inducing anti-tumor responses. The speakers will use PowerPoint formats to present illustrative cases, to review clinical trials where anti-tumor responses were observed in association with graft rejection, and to present preclinical studies demonstrating possible immunobiological mechanisms of the anti-tumor effects
| || ||
|Single Viewer: On-Demand||
|Group Viewing: On-Demand||
Continuing Education Credit
AABB designates both the live and on-demand version of this eCast each eligible for 1 continuing education credit/contact hour for Physicians, General Participation, California Nurse, California Lab Personnel and Florida Lab Personnel. The number and type of credits awarded for this program (both live and on-demand) was determined by the program duration. For more information on each credit type please visit our Continuing Education Credits webpage.
Disclosures for the planners of this event can be found here. Disclosures for the program faculty are provided at the beginning of the program.
Dr. Bimalangshu (“Bimal”) Dey received his MD from the Semmelweis University Medical School. He completed his medical residency at the VA Medical Center in Salem, Virginia, and his hematology-oncology fellowship at the Massachusetts General Hospital. He is an Assistant Physician in the Bone Marrow Transplant Program at the MGH, an Associate Professor of Medicine at Harvard Medical School, and a faculty member of the MGH Center for Global Health. Since 2007, Dr. Dey has been actively engaged with the government of Bangladesh to strengthen public sector cancer care at the Dhaka Medical College Hospital and to enhance the status of public sector nursing through subspecialty training. Dr Dey’s research focus has been in the field of allogeneic bone marrow transplantation and graft vs host disease. He is the author of numerous publications on the pathobiology of GVHD in murine models an on mixed chimerism as a platform for cellular immunotherapy in man. He is an avid teacher of students and residents and has received multiple awards for his teaching excellence.